
DarioHealth Corp. (NASDAQ: DRIO) said Thursday that its board has begun a strategic review following unsolicited interest from potential partners.
The New York-based digital health company, which develops chronic condition management platforms, formed a special committee of independent directors to explore options, including a sale, merger, or continuation as a standalone business.